{"id":"NCT04073303","sponsor":"AbbVie","briefTitle":"BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence","officialTitle":"BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-29","primaryCompletion":"2022-11-10","completion":"2022-11-10","firstPosted":"2019-08-29","resultsPosted":"2025-05-06","lastUpdate":"2025-05-06"},"enrollment":377,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Masseter Muscle Prominence"],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum Toxin Type A","otherNames":["OnabotulinumtoxinA","BOTOX®"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Botulinum Toxin Type A (BOTOX®)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to evaluate the safety and effectiveness of administering BOTOX for the treatment of Masseter Muscle Prominence (MMP) in adults.","primaryOutcome":{"measure":"Achievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 90","timeFrame":"Day 90","effectByArm":[{"arm":"Placebo","deltaMin":2.2,"sd":null},{"arm":"BOTOX®","deltaMin":51.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":10},"locations":{"siteCount":21,"countries":["Canada","China","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":93},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","MASTICATION DISORDER","HEADACHE"]}}